AstraZeneca asthma drug Fasenra meets endpoints in Phase 3 trial
AstraZeneca
12,050.00p
16:49 03/05/24
AstraZeneca said on Thursday that its Fasenra asthma drug met both co-primary endpoints in a phase III trial for patients with chronic rhinosinusitis with nasal polyps.
FTSE 100
8,213.49
16:59 03/05/24
FTSE 350
4,515.50
16:54 03/05/24
FTSE All-Share
4,469.09
16:50 03/05/24
Pharmaceuticals & Biotechnology
23,112.61
16:54 03/05/24
The trial showed that compared with placebo, the drug led to a significant improvement in the size of nasal polyps and in nasal blockage in patients with severe bilateral nasal polyposis who were still symptomatic despite continued treatment with standard of care.
Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said: "Patients with chronic rhinosinusitis with nasal polyps suffer significantly with nasal congestion and a reduced quality of life. Current treatments, such as intranasal or oral corticosteroids and surgery to remove polyps, do not fully address patient needs.
"The OSTRO data indicate Fasenra can benefit patients with nasal polyps. We look forward to completing the full analysis and sharing these results at an upcoming medical meeting."
Chronic rhinosinusitis with nasal polyps is characterised by persistent inflammation of the mucous membrane lining the nasal passages and sinuses accompanied by benign growths, called nasal polyps. Nasal polyps can block nasal passages and lead to breathing problems, reduction in the sense of smell, nasal discharge, sleep disturbance and other adverse effects on quality of life.